(-)-Epigallocathechin-3-gallate, an AMPK activator, decreases ovariectomy-induced bone loss by suppression of bone resorption

Calcified Tissue International

Volumn 90, Issue 5, 2012, Pages 404-410

  Lee, Seung Hun ^a   Kim, Beom Jun ^a   Choi, Hyung Jin ^b   Cho, Sun Wook ^b   Shin, Chan Soo ^b   Park, Sook Young ^c   Lee, Young Sun ^c   Lee, Sun Young ^c   Kim, Hong Hee ^b   Kim, Ghi Su ^a   Koh, Jung Min ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Asan Institute for Life Sciences   (South Korea)

Author keywords

( ) Epigallocathechin 3 gallate; AMP activated protein kinase; Bone resorption; Osteoclast

Indexed keywords

EPIGALLOCATECHIN GALLATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CALVARIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; FEMUR; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RISK REDUCTION; SHAM PROCEDURE; TISSUE DISTRIBUTION; TRABECULAR BONE; WEIGHT GAIN; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BODY WEIGHT; BONE DENSITY; BONE RESORPTION; CATECHIN; ENZYME ACTIVATORS; FEMALE; MICE; OVARIECTOMY; PROTEASE INHIBITORS;

EID: 84862805995     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-012-9584-7     Document Type: Article

References (42)

1. M Zaidi 2007 Skeletal remodeling in health and disease Nat Med 13 791 801 17618270 10.1038/nm1593 1:CAS:528:DC%2BD2sXnsFWmtro%3D (Pubitemid 47038187)
2. D Brown S Breton 1996 Mitochondria-rich, proton-secreting epithelial cells J Exp Biol 199 2345 2358 9114500 1:CAS:528:DyaK2sXjs1Wktg%3D%3D (Pubitemid 27040248)
3. E Canalis A Giustina JP Bilezikian 2007 Mechanisms of anabolic therapies for osteoporosis N Engl J Med 357 905 916 17761594 10.1056/NEJMra067395 1:CAS:528:DC%2BD2sXpvVylurk%3D (Pubitemid 47347324)
4. G Zhou IK Sebhat BB Zhang 2009 AMPK activators: potential therapeutics for metabolic and other diseases Acta Physiol (Oxf) 196 175 190 10.1111/j.1748-1716.2009.01967.x 1:CAS:528:DC%2BD1MXlt1KrtLY%3D
5. JM Quinn S Tam NA Sims H Saleh NE McGregor IJ Poulton JW Scott MT Gillespie BE Kemp BJ van Denderen 2010 Germline deletion of AMP-activated protein kinase beta subunits reduces bone mass without altering osteoclast differentiation or function FASEB J 24 275 285 19723702 10.1096/fj.09-137158
6. M Shah B Kola A Bataveljic TR Arnett B Viollet L Saxon M Korbonits C Chenu 2010 AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass Bone 47 309 319 20399918 10.1016/j.bone.2010.04.596 1:CAS:528:DC%2BC3cXos1Cgsrs%3D
7. CH Hou TW Tan CH Tang 2008 AMP-activated protein kinase is involved in COX-2 expression in response to ultrasound in cultured osteoblasts Cell Signal 20 978 988 18276112 10.1016/j.cellsig.2008.01.013 1:CAS:528:DC%2BD1cXjtVWisbc%3D
8. I Kanazawa T Yamaguchi S Yano M Yamauchi T Sugimoto 2008 Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression Biochem Biophys Res Commun 375 414 419 18721796 10.1016/j.bbrc.2008.08.034 1:CAS:528: DC%2BD1cXhtFaqs7nE
9. I Kanazawa T Yamaguchi S Yano M Yamauchi T Sugimoto 2009 Activation of AMP kinase and inhibition of Rho kinase induce the mineralization of osteoblastic MC3T3-E1 cells through endothelial NOS and BMP-2 expression Am J Physiol Endocrinol Metab 296 E139 E146 19001547 10.1152/ajpendo.90677.2008 1:CAS:528:DC%2BD1MXpsFCnsw%3D%3D
10. I Kanazawa T Yamaguchi S Yano M Yamauchi M Yamamoto T Sugimoto 2007 Adiponectin and AMP kinase activator stimulate proliferation, differentiation, and mineralization of osteoblastic MC3T3-E1 cells BMC Cell Biol 8 51 18047638 10.1186/1471-2121-8-51
11. T Kasai K Bandow H Suzuki N Chiba K Kakimoto T Ohnishi S Kawamoto E Nagaoka T Matsuguchi 2009 Osteoblast differentiation is functionally associated with decreased AMP kinase activity J Cell Physiol 221 740 749 19725053 10.1002/jcp.21917 1:CAS:528:DC%2BD1MXhtF2qtb3L
12. YS Lee YS Kim SY Lee GH Kim BJ Kim SH Lee KU Lee GS Kim SW Kim JM Koh 2010 AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts Bone 47 926 937 20696287 10.1016/j.bone.2010.08.001 1:CAS:528:DC%2BC3cXht1Kqs7vL
13. EF Eriksen B Langdahl A Vesterby J Rungby M Kassem 1999 Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women J Bone Miner Res 14 1217 1221 10404024 10.1359/jbmr.1999.14.7.1217 1:CAS:528:DyaK1MXkvVyjsbg%3D (Pubitemid 29314067)
14. G Khastgir J Studd N Holland J Alaghband-Zadeh S Fox J Chow 2001 Anabolic effect of estrogen replacement on bone in postmenopausal women with osteoporosis: histomorphometric evidence in a longitudinal study J Clin Endocrinol Metab 86 289 295 11232014 10.1210/jc.86.1.289 1:CAS:528: DC%2BD3MXhtVGnsbs%3D (Pubitemid 32109808)
15. N Musi MF Hirshman J Nygren M Svanfeldt P Bavenholm O Rooyackers G Zhou JM Williamson O Ljunqvist S Efendic DE Moller A Thorell LJ Goodyear 2002 Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes Diabetes 51 2074 2081 12086935 10.2337/diabetes.51.7.2074 1:CAS:528:DC%2BD38Xlt1WltrY%3D (Pubitemid 34729010)
16. G Zhou R Myers Y Li Y Chen X Shen J Fenyk-Melody M Wu J Ventre T Doebber N Fujii N Musi MF Hirshman LJ Goodyear DE Moller 2001 Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 1167 1174 11602624 1:CAS:528:DC%2BD3MXns1ChsL4%3D (Pubitemid 32995375)
17. J Yin H Xing J Ye 2008 Efficacy of berberine in patients with type 2 diabetes mellitus Metabolism 57 712 717 18442638 10.1016/j.metabol.2008.01.013 1:CAS:528:DC%2BD1cXlslWiu7g%3D (Pubitemid 351608234)
18. MS Kim JY Park C Namkoong PG Jang JW Ryu HS Song JY Yun IS Namgoong J Ha IS Park IK Lee B Viollet JH Youn HK Lee KU Lee 2004 Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase Nat Med 10 727 733 15195087 10.1038/nm1061 1:CAS:528:DC%2BD2cXlt1Gjsbs%3D (Pubitemid 38937638)
19. X Hou S Xu KA Maitland-Toolan K Sato B Jiang Y Ido F Lan K Walsh M Wierzbicki TJ Verbeuren RA Cohen M Zang 2008 SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase J Biol Chem 283 20015 20026 18482975 10.1074/jbc.M802187200 1:CAS:528:DC%2BD1cXotlOitL0%3D
20. QF Collins HY Liu J Pi Z Liu MJ Quon W Cao 2007 Epigallocatechin-3- gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5′-AMP-activated protein kinase J Biol Chem 282 30143 30149 17724029 10.1074/jbc.M702390200 1:CAS:528:DC%2BD2sXhtFagtbbO (Pubitemid 350035266)
21. Q Mai Z Zhang S Xu M Lu R Zhou L Zhao C Jia Z Wen D Jin X Bai 2011 Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats J Cell Biochem 112 2902 2909 21618594 10.1002/jcb.23206 1:CAS:528:DC%2BC3MXhtFyqtrbE
22. L Qin T Han Q Zhang D Cao H Nian K Rahman H Zheng 2008 Antiosteoporotic chemical constituents from Er-Xian decoction, a traditional Chinese herbal formula J Ethnopharmacol 118 271 279 18501540 10.1016/j.jep.2008.04.009 1:CAS:528:DC%2BD1cXns1agur4%3D
23. ZP Liu WX Li B Yu J Huang J Sun JS Huo CX Liu 2005 Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model J Med Food 8 14 19 15857203 10.1089/jmf.2005.8.14 1:CAS:528:DC%2BD2MXjsFCnsr0%3D (Pubitemid 40617031)
24. SH Lee MJ Kim BJ Kim SR Kim S Chun JS Ryu GS Kim MC Lee JM Koh SJ Chung 2010 Homocysteine-lowering therapy or antioxidant therapy for bone loss in Parkinson's disease Mov Disord 25 332 340 19938151 10.1002/mds.22866
25. D Mereles W Hunstein 2011 Epigallocatechin-3-gallate (EGCG) for clinical trials: more pitfalls than promises? Int J Mol Sci 12 5592 5603 22016611 10.3390/ijms12095592 1:CAS:528:DC%2BC3MXht1entbzP
26. SM Cadarette AM Burden 2010 Measuring and improving adherence to osteoporosis pharmacotherapy Curr Opin Rheumatol 22 397 403 20498602 10.1097/BOR.0b013e32833ac7fe
27. ME Stearns MD Amatangelo D Varma C Sell SM Goodyear 2010 Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice Am J Pathol 177 3169 3179 20971741 10.2353/ajpath.2010. 100330 1:CAS:528:DC%2BC3MXis1Kisw%3D%3D
28. AM Parfitt MK Drezner FH Glorieux JA Kanis H Malluche PJ Meunier SM Ott RR Recker 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee J Bone Miner Res 2 595 610 3455637 10.1002/jbmr.5650020617 1:STN:280: DyaL1czjvVemsQ%3D%3D
29. JH Lee H Jin HE Shim HN Kim H Ha ZH Lee 2010 Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal Mol Pharmacol 77 17 25 19828731 10.1124/mol.109.057877 1:CAS:528:DC%2BC3cXovFymug%3D%3D
30. JE Kim MW Ahn SH Baek IK Lee YW Kim JY Kim JM Dan SY Park 2008 AMPK activator, AICAR, inhibits palmitate-induced apoptosis in osteoblast Bone 43 394 404 18502715 10.1016/j.bone.2008.03.021 1:CAS:528:DC%2BD1cXosVOitLw%3D
31. T Martin JH Gooi NA Sims 2009 Molecular mechanisms in coupling of bone formation to resorption Crit Rev Eukaryot Gene Expr 19 73 88 19191758 1:CAS:528:DC%2BD1MXjt1Sisbs%3D
32. K Matsuo N Irie 2008 Osteoclast: osteoblast communication Arch Biochem Biophys 473 201 209 18406338 10.1016/j.abb.2008.03.027 1:CAS:528: DC%2BD1cXlsFOgtbs%3D
33. YH Kao RA Hiipakka S Liao 2000 Modulation of endocrine systems and food intake by green tea epigallocatechin gallate Endocrinology 141 980 987 10698173 10.1210/en.141.3.980 1:CAS:528:DC%2BD3cXisFOrsLk%3D (Pubitemid 32260441)
34. C Nelson-Dooley MA Della-Fera M Hamrick CA Baile 2005 Novel treatments for obesity and osteoporosis: targeting apoptotic pathways in adipocytes Curr Med Chem 12 2215 2225 16178781 10.2174/0929867054864886 1:CAS:528: DC%2BD2MXpsVegurc%3D (Pubitemid 41179708)
35. S Wolfram Y Wang F Thielecke 2006 Anti-obesity effects of green tea: from bedside to bench Mol Nutr Food Res 50 176 187 16470636 10.1002/mnfr.200500102 1:CAS:528:DC%2BD28XisVaitbg%3D (Pubitemid 43325659)
36. MW Hamrick SL Ferrari 2008 Leptin and the sympathetic connection of fat to bone Osteoporos Int 19 905 912 17924050 10.1007/s00198-007-0487-9 1:CAS:528:DC%2BD1cXmsFKnuro%3D (Pubitemid 351758616)
37. MC Carr 2003 The emergence of the metabolic syndrome with menopause J Clin Endocrinol Metab 88 2404 2411 12788835 10.1210/jc.2003-030242 1:CAS:528:DC%2BD3sXkslCktb0%3D (Pubitemid 36724404)
38. AM Hill AM Coates JD Buckley R Ross F Thielecke PR Howe 2007 Can EGCG reduce abdominal fat in obese subjects? J Am Coll Nutr 26 396S 402S 17906193 1:CAS:528:DC%2BD2sXht1emu7zI (Pubitemid 47579909)
39. CL Shen JK Yeh BJ Stoecker MC Chyu JS Wang 2009 Green tea polyphenols mitigate deterioration of bone microarchitecture in middle-aged female rats Bone 44 684 690 19118658 10.1016/j.bone.2008.11.018 1:CAS:528:DC%2BD1MXjt1aktbk%3D
40. CL Shen JK Yeh JJ Cao OL Tatum RY Dagda JS Wang 2011 Green tea polyphenols mitigate bone loss of female rats in a chronic inflammation-induced bone loss model J Nutr Biochem 21 968 974 10.1016/j.jnutbio.2009.08.002
41. S Kim MJ Lee J Hong C Li TJ Smith GY Yang DN Seril CS Yang 2000 Plasma and tissue levels of tea catechins in rats and mice during chronic consumption of green tea polyphenols Nutr Cancer 37 41 48 10965518 10.1207/S15327914NC3701-5 1:CAS:528:DC%2BD3cXmtFOms7k%3D (Pubitemid 30650665)
42. A Peairs R Dai L Gan S Shimp MN Rylander L Li CM Reilly 2010 Epigallocatechin-3-gallate (EGCG) attenuates inflammation in MRL/lpr mouse mesangial cells Cell Mol Immunol 7 123 132 20140007 1:CAS:528: DC%2BC3cXisFelsrw%3D